MDA5 is SUMOylated by PIAS2β in the upregulation of Type I interferon signaling

Molecular Immunology

Volumn 48, Issue 4, 2011, Pages 415-422

  Fu, Jihuan ^a,b   Xiong, Yanbao ^a,b   Xu, Youli ^a   Cheng, Genhong ^a,c   Tang, Hong ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

IFNs; MDA5; SUMOylation; Ubiquitylation

Indexed keywords

INTERFERON; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 PROTEIN; PROTEIN; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN UBC9; RETINOIC ACID INDUCIBLE PROTEIN I; SUMO 1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SUMOYLATION; VIRUS REPLICATION;

CELL LINE; DEAD-BOX RNA HELICASES; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERFERON TYPE I; POLY I-C; PROTEIN BINDING; PROTEIN INHIBITORS OF ACTIVATED STAT; SIGNAL TRANSDUCTION; SUMOYLATION; UBIQUITINATION; UP-REGULATION;

EID: 78650609675     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.09.003     Document Type: Article

References (61)

1. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
2. Andrejeva J., Childs K.S., Young D.F., Carlos T.S., Stock N., Goodbourn S., Randall R.E. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:17264-17269.
3. Arimoto K., Takahashi H., Hishiki T., Konishi H., Fujita T., Shimotohno K. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:7500-7505.
4. Bergink S., Jentsch S. Principles of ubiquitin and SUMO modifications in DNA repair. Nature 2009, 458:461-467.
5. Carter S., Vousden K.H. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 2008, 7:2519-2528.
6. Desterro J.M., Rodriguez M.S., Hay R.T. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol. Cell 1998, 2:233-239.
7. Friedman C.S., O'Donnell M.A., Legarda-Addison D., Ng A., Cardenas W.B., Yount J.S., Moran T.M., Basler C.F., Komuro A., Horvath C.M., Xavier R., Ting A.T. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 2008, 9:930-936.
8. Gack M.U., Shin Y.C., Joo C.H., Urano T., Liang C., Sun L., Takeuchi O., Akira S., Chen Z., Inoue S., Jung J.U. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007, 446:916-920.
9. Gao D., Yang Y.K., Wang R.P., Zhou X., Diao F.C., Li M.D., Zhai Z.H., Jiang Z.F., Chen D.Y. REUL is a novel E3 ubiquitin ligase and stimulator of retinoic-acid-inducible gene-I. PLoS One 2009, 4:e5760.
10. Gitlin L., Barchet W., Gilfillan S., Cella M., Beutler B., Flavell R.A., Diamond M.S., Colonna M. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8459-8464.
11. Guo B., Cheng G. Modulation of the interferon antiviral response by the TBK1/IKKi adaptor protein TANK. J. Biol. Chem. 2007, 282:11817-11826.
12. Guo Y., Yang M.C., Weissler J.C., Yang Y.S. Modulation of PLAGL2 transactivation activity by Ubc9 co-activation not SUMOylation. Biochem. Biophys. Res. Commun. 2008, 374:570-575.
13. Hahn S.L., Wasylyk B., Criqui-Filipe P. Modulation of ETS-1 transcriptional activity by huUBC9, a ubiquitin-conjugating enzyme. Oncogene 1997, 15:1489-1495.
14. Haracska L., Torres-Ramos C.A., Johnson R.E., Prakash S., Prakash L. Opposing effects of ubiquitin conjugation and SUMO modification of PCNA on replicational bypass of DNA lesions in Saccharomyces cerevisiae. Mol. Cell Biol. 2004, 24:4267-4274.
15. Hay R.T. Modifying NEMO. Nat. Cell Biol. 2004, 6:89-91.
16. Hay R.T. SUMO: a history of modification. Mol. Cell 2005, 18:1-12.
17. Hay R.T. SUMO-specific proteases: a twist in the tail. Trends Cell Biol. 2007, 17:370-376.
18. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
19. Hornung V., Ellegast J., Kim S., Brzozka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.K., Schlee M., Endres S., Hartmann G. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
20. Huang J., Liu T., Xu L.G., Chen D., Zhai Z., Shu H.B. SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-triggered IRF-3 activation pathways. Embo J. 2005, 24:4018-4028.
21. Hunter T., Sun H. Crosstalk between the SUMO and ubiquitin pathways. Ernst Schering Found Symp. Proc. 2008, 1-16.
22. Kang D.C., Gopalkrishnan R.V., Lin L., Randolph A., Valerie K., Pestka S., Fisher P.B. Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene. Oncogene 2004, 23:1789-1800.
23. Kang D.C., Gopalkrishnan R.V., Wu Q., Jankowsky E., Pyle A.M., Fisher P.B. mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:637-642.
24. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., Tsujimura T., Takeda K., Fujita T., Takeuchi O., Akira S. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23:19-28.
25. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., Yamaguchi O., Otsu K., Tsujimura T., Koh C.S., Reis e Sousa C., Matsuura Y., Fujita T., Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.
26. Kawai T., Akira S. Innate immune recognition of viral infection. Nat. Immunol. 2006, 7:131-137.
27. Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K.J., Takeuchi O., Akira S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 2005, 6:981-988.
28. Kayagaki N., Phung Q., Chan S., Chaudhari R., Quan C., O'Rourke K.M., Eby M., Pietras E., Cheng G., Bazan J.F., Zhang Z., Arnott D., Dixit V.M. DUBA: a deubiquitinase that regulates type I interferon production. Science 2007, 318:1628-1632.
29. Kim M.J., Hwang S.Y., Imaizumi T., Yoo J.Y. Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation. J. Virol. 2008, 82:1474-1483.
30. Komuro A., Bamming D., Horvath C.M. Negative regulation of cytoplasmic RNA-mediated antiviral signaling. Cytokine 2008, 43:350-358.
31. Kubota T., Matsuoka M., Chang T.H., Tailor P., Sasaki T., Tashiro M., Kato A., Ozato K. Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J. Biol. Chem. 2008, 283:25660-25670.
32. Liu B., Liao J., Rao X., Kushner S.A., Chung C.D., Chang D.D., Shuai K. Inhibition of Stat1-mediated gene activation by PIAS1. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:10626-10631.
33. Liu B., Mink S., Wong K.A., Stein N., Getman C., Dempsey P.W., Wu H., Shuai K. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat. Immunol. 2004, 5:891-898.
34. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172.
35. Oshiumi H., Matsumoto M., Hatakeyama S., Seya T. Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection. J. Biol. Chem. 2009, 284:807-817.
36. Perry A.K., Chen G., Zheng D., Tang H., Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res. 2005, 15:407-422.
37. Poukka H., Aarnisalo P., Karvonen U., Palvimo J.J., Janne O.A. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J. Biol. Chem. 1999, 274:19441-19446.
38. Rodriguez M.S., Dargemont C., Hay R.T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 2001, 276:12654-12659.
39. Rubinson D.A., Dillon C.P., Kwiatkowski A.V., Sievers C., Yang L., Kopinja J., Rooney D.L., Zhang M., Ihrig M.M., McManus M.T., Gertler F.B., Scott M.L., Van Parijs L. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 2003, 33:401-406.
40. Rytinki M.M., Kaikkonen S., Pehkonen P., Jaaskelainen T., Palvimo J.J. PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol. Life Sci. 2009.
41. Saito T., Hirai R., Loo Y.M., Owen D., Johnson C.L., Sinha S.C., Akira S., Fujita T., Gale M. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:582-587.
42. Sampson D.A., Wang M., Matunis M.J. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 2001, 276:21664-21669.
43. Schmidt D., Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc. Natl. Acad. Sci. U.S.A. 2002, 99.
44. Seth R.B., Sun L., Ea C.K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122:669-682.
45. Shuai K., Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat. Rev. Immunol. 2005, 5:593-605.
46. Song J., Durrin L.K., Wilkinson T.A., Krontiris T.G., Chen Y. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:14373-14378.
47. Song J., Zhang Z., Hu W., Chen Y. Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation. J. Biol. Chem. 2005, 280:40122-40129.
48. Sui G., Shi Y. Gene silencing by a DNA vector-based RNAi technology. Methods Mol. Biol. 2005, 309:205-218.
49. Tahk S., Liu B., Chernishof V., Wong K.A., Wu H., Shuai K. Control of specificity and magnitude of NF-kappa B and STAT1-mediated gene activation through PIASy and PIAS1 cooperation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:11643-11648.
50. Uematsu S., Akira S. Toll-like receptors and innate immunity. J. Mol. Med. 2006, 84:712-725.
51. Ungureanu D., Vanhatupa S., Gronholm J., Palvimo J.J., Silvennoinen O. SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. Blood 2005, 106:224-226.
52. Wang C., Chen T., Zhang J., Yang M., Li N., Xu X., Cao X. The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated production of type I interferon. Nat. Immunol. 2009, 10:744-752.
53. Weng C., Li Y., Xu D., Shi Y., Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J. Biol. Chem. 2005, 280:10491-10500.
54. Xu L.G., Wang Y.Y., Han K.J., Li L.Y., Zhai Z., Shu H.B. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 2005, 19:727-740.
55. Yang S.H., Jaffray E., Hay R.T., Sharrocks A.D. Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol. Cell 2003, 12:63-74.
56. Yang S.H., Sharrocks A.D. PIASx acts as an Elk-1 coactivator by facilitating derepression. Embo J. 2005, 24:2161-2171.
57. Yoneyama M., Fujita T. Structural mechanism of RNA recognition by the RIG-I-like receptors. Immunity 2008, 29:178-181.
58. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 2004, 5:730-737.
59. Zhang J., Xu L.G., Han K.J., Wei X., Shu H.B. PIASy represses TRIF-induced ISRE and NF-kappaB activation but not apoptosis. FEBS Lett. 2004, 570:97-101.
60. Zhang M., Tian Y., Wang R.P., Gao D., Zhang Y., Diao F.C., Chen D.Y., Zhai Z.H., Shu H.B. Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3. Cell Res. 2008, 18:1096-1104.
61. Zheng D., Chen G., Guo B., Cheng G., Tang H. PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res. 2008, 18:1105-1113.